Benchmarks for success in focal therapy of prostate cancer: Cure or control?

World Journal of Urology

Volumn 28, Issue 5, 2010, Pages 577-582

  Ahmed, Hashim U ^a   Emberton, Mark ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

Author keywords

Active surveillance; Focal therapy; Index lesion; Multi parametric MRI; Prostate cancer; Prostate transperineal template mapping biopsy; Radical therapy

Indexed keywords

ABLATION THERAPY; ARTICLE; HEALTH CARE QUALITY; HUMAN; MALE; OUTCOME ASSESSMENT; PROSTATE TUMOR; QUALITY CONTROL; STANDARD; TREATMENT OUTCOME;

ABLATION TECHNIQUES; BENCHMARKING; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATIC NEOPLASMS; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 77957107070     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0590-y     Document Type: Article

References (28)

1. Ahmed HU, Pendse D, Illing R et al (2007) Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 4(11): 632-642.
2. Ahmed HU, Moore C, Emberton M (2009) Minimally-invasive technologies in uro-oncology: The role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol Oxford 18(3): 219-232.
3. Ahmed HU, Emberton M (2010) Is focal therapy the future for prostate cancer? Future Oncol 6(2): 261-268.
4. Schroeder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European Study. N Engl J Med 360(13): 1320-1328.
5. D'Amico AV, Whittington R, Malkowicz SB et al (2000) Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer. Prostate Cancer Prostatic Dis 3(4): 259-264.
6. Epstein JI, Walsh PC, Carmichael M et al (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. Jama 271(5): 368-374.
7. Kattan MW, Eastham JA, Stapleton AM et al (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90(10): 766-771.
8. Parker C, Muston D, Melia J et al (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94(10): 1361-1368.
9. Sakr WA, Grignon DJ, Crissman JD et al (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 8(3): 439-443.
10. Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. Jama 302(15): 1685-1692.
11. Stamey TA, Freiha FS, Mcneal JE et al (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71(3 Suppl): 933-938.
12. Livni N, Winkler M, Abel P, Ivni N, Beckley I, Ahmed HU (2010) Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis (epub).
13. Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M (2010) The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int (epub).
14. Ahmed HU (2009) The index lesion and the origin of prostate cancer. N Engl J Med 361(17): 1704-1706.
15. Ahmed HU, Kirkham A, Arya M et al (2009) Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 6(4): 197-206.
16. Onik G, Miessau M, Bostwick DG (2009) Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 27(26): 4321-4326.
17. Eggener S, Salomon G, Scardino P, de la Rosette J, Polascik T, Brewster S (2010) Focal Therapy for prostate cancer: possibilities and limitations. Eur Urol (epub).
18. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28(7): 1117-1123.
19. Klotz L, Zhang L, Lam A et al (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28(1): 126-131.
20. Ahmed HU, Moore C, Lecornet E et al (2010) Focal therapy in prostate cancer: determinants of success and failure. J Endourol 24(5): 819-825.
21. Roach M, Hanks G, Thames HJ et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4): 965-974.
22. van As NJ, Parker CC (2007) Active surveillance with selective radical treatment for localized prostate cancer. Cancer J 13(5): 289-294.
23. Ng MK, van As N, Thomas K et al (2009) Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int 103(7): 872-876.
24. Donnelly BJ, Saliken JC, Brasher PMA et al (2010) A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 116(2): 323-330.
25. Brubaker L, Moalli P, Richter HE et al (2009) Challenges in designing a pragmatic clinical trial: the mixed incontinence-medical or surgical approach (MIMOSA) trial experience. Clin Trials 6(4): 355-364.
26. Chambers BR, Donnan GA (2005) Carotid endarterectomy for asymptomatic carotid stenosis. Cochrane Database Syst Rev (4): CD001923.
27. Blazeby JM, Barham CP, Donovan JL (2008) Commentary: randomised trials of surgical and non-surgical treatment: a role model for the future. Bmj 337: a2747.
28. Treweek S, Zwarenstein M (2009) Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 10: 37.